FDA clearance of Investigational New Drug Application for novel peanut allergy vaccine
January 26, 2022Research and Development
Allergy Therapeutics has announced the FDA clearance of the Investigational New Drug Application (IND) for its novel virus-like particle (VLP)-based …
Highest UK COVID-19 deaths since February as Pfizer begin trials for Omicron jab
January 26, 2022Research and Development
Pfizer has begun clinical trials for its new COVID-19 vaccine tailored to the Omicron variant, and has shared that it …
Maxim Biomedical receives EUA for ClearDetect COVID-19 antigen home test
January 26, 2022Research and Development
Maxim Biomedical have received an Emergency Use Authorisation (EUA) from the FDA for their new ClearDetect COVID-19 Antigen Home Test. …
New study highlights cell power as a functional biomarker for preventing tumour escape
January 26, 2022Research and Development
LUMICKS announced that new research findings published in Translational Medicine detailed a novel design strategy for preventing tumour escape through …
FDA grants Evrysdi priority review for treatment of spinal muscular atrophy in infants
January 25, 2022Manufacturing and Production
The FDA has granted priority review of a supplemental new drug application (sNDA) for Evrysdi (risdiplam), to expand the indication …
Significantly reduced tumour growth with new candidate
January 25, 2022Manufacturing and Production
Spago Nanomedical AB announced new clinical and preclinical results for the company’s leading candidate drug, Tumorad® (177Lu-SN201). In a preclinical …
Bimzelx approved in Japan for treatment of multiple types of psoriasis
January 25, 2022Manufacturing and Production
UCB announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorisation for BIMZELX (bimekizumab) for …
FDA restrict use of two monoclonal antibody treatments
January 25, 2022Manufacturing and Production
The FDA has shared that it is limiting the use of two monoclonal antibody therapies for the treatment of COVID-19, …
Ascletis begins Phase III trial into bevacizumab for treatment of recurrent glioblastoma
January 24, 2022Sales and Marketing
Ascletis Pharma has announced the dosing of the first patient in the Phase III registration clinical trial of ASC40, combined …
Pfizer: Annual COVID shots preferable to frequent boosters
January 24, 2022Sales and Marketing
Pfizer CEO Albert Bourla has commented that an annual COVID-19 vaccine would be preferable to more frequent booster shots in …
NICE expands guidance for lokelma in adult patients with persistent hyperkalaemia
January 24, 2022Sales and Marketing
NICE have updated the Technology Appraisal Guidance (TAG) for Lokelma (sodium zirconium cyclosilicate SZC) in the treatment of adult patients …
Veklury obtains FDA approval for COVID-19 outpatients
January 24, 2022Sales and Marketing
The FDA has granted expedited approval of a supplemental new drug application (sNDA) for Veklury (remdesivir) for he treatment of …
EU health ministers consider fourth COVID-19 vaccine dose
January 21, 2022Medical Communications
European Union health ministers will try to find a common line on Friday over a potential fourth dose of COVID-19 …
Amid plans to ease COVID restrictions, dialysis patients remain vulnerable to Omicron
January 21, 2022Medical Communications
As the government in England relaxes COVID-19 restrictions, new data from the Francis Crick Institute raise concerns over the impact …
Artificial pancreas may prove life-changing for young children with diabetes
January 21, 2022Medical Communications
Cambridge researchers have developed an artificial pancreas which may beat standard treatment in controlling Type 1 diabetes in young children. …
Clover reveals positive data from Phase II/III COVID-19 vaccine trial
January 21, 2022Medical Communications
Clover Biopharmaceuticals has announced that final efficacy data from SPECTRA, a global Phase II/III clinical trial into its COVID-19 vaccine …
LUMAKRAS (sotorasib) receives approval in Japan for lung cancer patients
January 20, 2022Business Services
Amgen has announced that LUMAKRAS received approval in Japan for the treatment of patients with KRAS G12C-mutated advanced non-small cell …
All Plan B restrictions to end in England
January 20, 2022Business Services
Prime Minister Boris Johnson has announced that England’s Plan B measures are to end from 26 January. This will include …
1.27 million deaths a year attributable to antimicrobial resistance
January 20, 2022Business Services
The Global Research on Antimicrobial Resistance (GRAM) paper has revealed the true scale of antibiotic resistance in Western Europe, and …
Vaccine alliance Gavi says that additional $5.2bn needed to ensure supply
January 20, 2022Business Services
The chairman of the Gavi vaccine alliance, Jose Manuel Barroso, has said that an additional $5.2 billion is required to …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
